Abstract 183P
Background
In Asia, the standard treatment for locally advanced gastric cancer (LAGC) involves gastrectomy with D2 dissection and adjuvant chemotherapy. However, achieving adequate chemotherapy intensity after gastrectomy presents challenges. Previous trials have shown the effectiveness of neoadjuvant chemotherapy (NAC). Nevertheless, limited research has been conducted to explore the feasibility of NAC-SOX for older patients with LAGC. This phase II study (KSCC1801) aimed to assess the safety and efficacy of NAC-SOX in LAGC patients aged ≥ 70 years. Herein, we present the conclusive data analysis of KSCC1801, shedding light on its outcomes.
Methods
Patients received NAC consisting of three cycles of SOX130 (oxaliplatin 130 mg/m2 on day 1, oral S-1 40-60 mg twice daily for two weeks every three weeks), followed by gastrectomy with lymph node dissection. The primary endpoint was the dose intensity (DI) of the treatment. Secondary endpoints included safety, R0 resection rate, pathological response rate (pRR), overall survival, and relapse-free survival.
Results
The study enrolled 26 patients with a median age of 74.5 years. The median DI in the NAC-SOX130 treatment was 97.2% for S-1 and 98.3% for oxaliplatin. NAC was successfully administered to 25 patients (96.2%), among whom 24 (92.3%) underwent gastrectomy with lymphadenectomy. The R0 resection rate was 92.3%, and the pRR (≥ grade 1b) was 62.5%. Major adverse events (≥ grade 3) included neutropenia (20.0%), thrombocytopenia (11.5%), anorexia (11.5%), nausea (7.7%), and hyponatremia (7.7%). Postoperative complications such as abdominal infection, elevated blood amylase, and bacteremia occurred in one patient each. The 1- and 2-year OS rates were 93.3% and 89.7%, respectively. The 1- and 2-year RFS rates were 68.7% and 58.6%, respectively.
Conclusions
NAC-SOX130 proves to be a feasible therapy for older patients aged ≥ 70 years.
Clinical trial identification
jRCTs071180001.
Editorial acknowledgement
Legal entity responsible for the study
KSCC (Kyushu Study group of Clinical Cancer).
Funding
Yakult Honsha.
Disclosure
E. Oki: Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical Co. Ltd., Ono Pharmaceutical Co. Ltd., Chugai Pharmaceutical Co. Ltd., Bayer, Eli Lilly, Bristol-myers Squibbb, MSD; Financial Interests, Personal and Institutional, Research Grant: Guardant Health. All other authors have declared no conflicts of interest.
Resources from the same session
153P - IMbrave150: Exploratory analyses for investigating associations between overall survival (OS) and depth of response (DpR) or duration of response (DoR) in patients (pts) with unresectable hepatocellular carcinoma (HCC)
Presenter: Masatoshi Kudo
Session: Poster Display
Resources:
Abstract
154P - Adverse events (AEs) as potential predictive factors of activity in patients with advanced hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab (AB)
Presenter: Mara Persano
Session: Poster Display
Resources:
Abstract
155P - Penpulimab combined with anlotinib and nab-paclitaxel plus gemcitabine (PAAG) as first-line treatment for advanced metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase II study
Presenter: Juan Du
Session: Poster Display
Resources:
Abstract
156P - Phase II trial of second-line regorafenib in patients with unresectable hepatocellular carcinoma after progression on first-line atezolizumab plus bevacizumab: REGONEXT trial
Presenter: Jaekyung Cheon
Session: Poster Display
Resources:
Abstract
157P - T/N ratio and radiation dose delivered do not correlate with the development of Radioembolization-Induced Liver Disease (REILD) in Hepatocellular Carcinoma (HCC) following Y90 selective internal radiation therapy (Y90-SIRT): A retrospective, single tertiary centre cohort study
Presenter: Daniel Yang Yao Peh
Session: Poster Display
Resources:
Abstract
158P - Single-cell RNA sequencing via Endoscopic Ultrasoundguided Fine-Needle Biopsy (EUS-FNB) Pancreatic Biopsies uncovered an aggressive subclone with a poor prognosis
Presenter: Yung-yeh Su
Session: Poster Display
Resources:
Abstract
159P - Classical computer vision and modern deep-learning of pancreatic stroma histology features to diagnose cancer
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
160P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nano-liposomal irinotecan with fluorouracil and folinic acid for advanced pancreatic cancer
Presenter: Wataru Kusano
Session: Poster Display
Resources:
Abstract
161P - Screening and COnsensus based on Practices and Evidence (SCOPE): Real-world survey on Japanese and rest-of-world practice patterns in resectable pancreatic cancer
Presenter: Elizabeth Smyth
Session: Poster Display
Resources:
Abstract
162P - Recurrence pattern of hepatocellular carcinoma patients receiving curative surgery of RFA: An update
Presenter: Long Chan
Session: Poster Display
Resources:
Abstract